TARRYTOWN, N.Y., Sept. 17, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed results from the Phase 3 VIVID and VISTA trials of EYLEA ® (aflibercept) Injection in Diabetic Macular Edema (DME) will be presented at an oral session during the upcoming annual meeting of the Retina Society to be held September 26-29 in Los Angeles, United States. These data will be presented on Friday, September 27, at 4:51 PM PDT. Separately, these data are also scheduled to be presented at an oral presentation on September 27, at 3:58 PM CEST, at the EURETINA Congress in Hamburg, Germany. Regeneron will host a webcast investor meeting on Saturday, September 28, at 7:00 AM PDT/ 10:00 AM EDT to discuss these data. The event will be webcast and can be accessed at www.regeneron.com or by dialing in via the following numbers: (888) 660-6127 (U.S. toll free) or (973) 890-8355 (international dial-in). EYLEA was approved in the United States for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD) in November 2011 and for Macular Edema following CRVO in September 2012. EYLEA has also been approved in Europe, Japan, Australia, and in several other countries for use in wet AMD and in Europe and selected countries in South America for Macular Edema following CRVO. Bayer HealthCare and Regeneron are collaborating on the global development of EYLEA. Regeneron maintains exclusive rights to EYLEA in the United States. Bayer HealthCare licensed the exclusive marketing rights outside the United States, where the companies share equally the profits from sales of EYLEA, except for Japan where Regeneron receives a royalty on net sales. About EYLEA ® (aflibercept) Injection for Intravitreal Injection Vascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in the body. Its normal role in a healthy organism is to trigger formation of new blood vessels (angiogenesis) supporting the growth of the body's tissues and organs. However, in certain diseases, such as wet age-related macular degeneration, it is also associated with the growth of abnormal new blood vessels in the eye, which exhibit abnormal increased permeability that leads to edema. Scarring and loss of fine-resolution central vision often results. In Central Retinal Vein Occlusion (CRVO), a blockage occurs in the main blood vessel that transports deoxygenated blood away from the retina. VEGF levels are elevated in response contributing to macular edema. In patients with diabetic macular edema (DME), hyperglycemia-induced vascular dysfunction and hypoxia result in elevated intraocular VEGF levels in the eye and resultant blood vessel permeability that leads to macular edema, which can result in vision loss. EYLEA is a recombinant fusion protein, consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. EYLEA acts as a soluble decoy receptor that binds VEGF-A and placental growth factor (PlGF) and thereby can inhibit the binding and activation of their cognate VEGF receptors.